IL-6 inhibition in RA — mechanism, monitoring, and differentiating the agents
IL-6 inhibitors can quiet RA—and mask CRP/ESR signals. Learn 4 monitoring clues on infection, lipids, neutrophils, and CDAI for safer care at the next visit.
Tapering biologics in RA — what the evidence supports
Considering RA biologic tapering? Learn why 6+ months of remission, no swollen joints, and dose spacing—not abrupt stopping—can help lower flare risk in RA.
Mycophenolate vs azathioprine in lupus maintenance
Prevent lupus relapse after induction: compare mycophenolate vs azathioprine using 2024 ACR/EULAR guidance, trial data, pregnancy safety & monitoring tips.
Methotrexate — why it remains the anchor DMARD after 40 years
Why methotrexate remains RA’s anchor after 40 years: proven inflammation control, low cost, predictable monitoring, and room to escalate safely.
Seronegative RA — diagnosis, prognosis, and treatment considerations
RF/anti-CCP negative? Learn how seronegative RA is diagnosed with 2010 criteria, imaging, and treat-to-target care—avoid mimics, missed synovitis, DMARD delays.
Lupus Fatigue: Why It Happens and What Helps
Fatigue is one of the most common and most debilitating symptoms reported by patients with systemic lupus erythematosus (SLE). Unlike
RA vs Osteoarthritis: Understanding the Difference
Joint pain is one of the most common reasons patients seek medical care — and one of the most frequently
Distinguishing inflammatory from non-inflammatory arthritis in primary care
Spot inflammatory arthritis early: 6 referral clues, 30–60+ min morning stiffness, boggy synovitis, focused labs and imaging to prevent joint damage sooner.
Hydroxychloroquine dosing and retinal toxicity — the updated guidance
Dose hydroxychloroquine safely with the 5 mg/kg actual-weight rule, retinal toxicity risk stats, OCT screening timing, and tips to protect lupus control well.
ANCA vasculitis remission induction — cyclophosphamide vs rituximab
Choose rituximab or Cytoxan for ANCA vasculitis with confidence: compare RAVE/RITUXVAS data, relapse, renal-lung urgency, fertility and toxicity tradeoffs.